New phase 3 data showed that patients with primary immune thrombocytopenia saw improved disease control when ianalumab was added to Promacta (eltrombopag) treatment compared to Promacta alone. Data ...
More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia (ITP), an autoimmune ...
The addition of ianalumab to eltrombopag significantly improved outcomes for patients with pretreated primary immune ...
ORLANDO -- Adding four monthly infusions of novel ianalumab helped adults with primary immune thrombocytopenia (ITP) achieve durable disease control in the second-line setting while stopping daily ...
Patients with immune thrombocytopenia (ITP) who received a first-in-class investigational drug in addition to standard ...
More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal ...
Dietary iron deficiency in mice alters lung T cell activation during influenza infection and leads to memory T cells that are ...
In a confirmatory model adjusted for baseline illness severity, the precision immunotherapy approach was associated with ...
In a recent preclinical study, researchers from The University of Texas MD Anderson Cancer Center developed an antibody ...
Enhertu (trastuzumab Deruxtecan [T-DXd]) treated patients continue to be eligible for enrollment in FLAMINGO-01. The Company believes that GLSI-100 will synergize with any trastuzumab based treatment ...
Lyell management will host an investor webcast with presenting author and ronde-cel investigator Sarah M. Larson, MD, ...
An evolutionary perspective on immune priming across plants and invertebrates highlights the roles of microbiomes and epigenetic regulation in shaping innate immune memory with promising applications ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback